A Microfluidics-Based Multiplex SERS Immunoassay Device for Analysis of Acute Ischemic Stroke Biomarkers.

IF 3.8 2区医学 Q1 CLINICAL NEUROLOGY

Translational Stroke Research Pub Date : 2025-04-01 Epub Date: 2023-11-21 DOI:10.1007/s12975-023-01204-x

Mengyue Wang, Huiyu Wan, Yanjiao Wang, Hui Yuan, Qingbin Ni, Baoliang Sun, Jingyi Sun, Ying Wang

{"title":"A Microfluidics-Based Multiplex SERS Immunoassay Device for Analysis of Acute Ischemic Stroke Biomarkers.","authors":"Mengyue Wang, Huiyu Wan, Yanjiao Wang, Hui Yuan, Qingbin Ni, Baoliang Sun, Jingyi Sun, Ying Wang","doi":"10.1007/s12975-023-01204-x","DOIUrl":null,"url":null,"abstract":"<p><p>Sensitive and accurate methods for early detection of acute ischemic stroke (AIS) are essential for timely treatment and prognostic assessment of patients. In this study, we report a microfluidics-based ultrasensitive surface-enhanced Raman scattering (SERS) immunoassay device for the quantitative determination of multiplex biomarkers in AIS. By preparing 5,5'-dithiobis-2-nitrobenzoic acid (DTNB) antibody-modified gold nanoparticles (AuNPs) on SERS devices as SERS probes, the biomarkers in whole blood of AIS were accurately captured and further visualized for SERS signal intensity quantitative analysis of six biomarkers in the blood samples. It is worth mentioning that the limit of detection (LOD) of the method can reach the level of fg/mL, with excellent sensitivity and selectivity. Meanwhile, the analytical comparison with ELISA method showed that the detection results of both methods were consistent, which verified the feasibility of the assembled device. The SERS immunoassay device detection provides a powerful strategy for the prediction, early diagnosis and dynamic monitoring of prognosis of AIS with a wide range of clinical practice prospects.</p>","PeriodicalId":23237,"journal":{"name":"Translational Stroke Research","volume":" ","pages":"217-226"},"PeriodicalIF":3.8000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Stroke Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12975-023-01204-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/21 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Sensitive and accurate methods for early detection of acute ischemic stroke (AIS) are essential for timely treatment and prognostic assessment of patients. In this study, we report a microfluidics-based ultrasensitive surface-enhanced Raman scattering (SERS) immunoassay device for the quantitative determination of multiplex biomarkers in AIS. By preparing 5,5'-dithiobis-2-nitrobenzoic acid (DTNB) antibody-modified gold nanoparticles (AuNPs) on SERS devices as SERS probes, the biomarkers in whole blood of AIS were accurately captured and further visualized for SERS signal intensity quantitative analysis of six biomarkers in the blood samples. It is worth mentioning that the limit of detection (LOD) of the method can reach the level of fg/mL, with excellent sensitivity and selectivity. Meanwhile, the analytical comparison with ELISA method showed that the detection results of both methods were consistent, which verified the feasibility of the assembled device. The SERS immunoassay device detection provides a powerful strategy for the prediction, early diagnosis and dynamic monitoring of prognosis of AIS with a wide range of clinical practice prospects.

Abstract Image

查看原文本刊更多论文

一种基于微流体的多重SERS免疫分析装置用于分析急性缺血性卒中生物标志物。

灵敏、准确的早期检测方法对于及时治疗和评估患者预后至关重要。在这项研究中，我们报道了一种基于微流体的超灵敏表面增强拉曼散射(SERS)免疫测定装置，用于定量测定AIS中的多种生物标志物。通过在SERS装置上制备5,5′-二硫比-2-硝基苯甲酸(DTNB)抗体修饰的金纳米颗粒(AuNPs)作为SERS探针，对AIS患者全血中的生物标志物进行准确捕获并进一步可视化，对血液样本中6种生物标志物进行SERS信号强度定量分析。值得一提的是，该方法的检出限(LOD)可达fg/mL级别，具有优良的灵敏度和选择性。同时与ELISA法进行分析比较，两种方法的检测结果一致，验证了组装装置的可行性。SERS免疫分析装置的检测为AIS的预测、早期诊断和动态监测预后提供了强有力的策略，具有广泛的临床应用前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational Stroke Research CLINICAL NEUROLOGY-NEUROSCIENCES

CiteScore

13.80

自引率

4.30%

发文量

130

审稿时长

6-12 weeks

期刊介绍： Translational Stroke Research covers basic, translational, and clinical studies. The Journal emphasizes novel approaches to help both to understand clinical phenomenon through basic science tools, and to translate basic science discoveries into the development of new strategies for the prevention, assessment, treatment, and enhancement of central nervous system repair after stroke and other forms of neurotrauma. Translational Stroke Research focuses on translational research and is relevant to both basic scientists and physicians, including but not restricted to neuroscientists, vascular biologists, neurologists, neuroimagers, and neurosurgeons.